GENOMED
A MEMBER OF SYNLAB

ONCOLOGY REQUEST FORM
-
SOLID TUMORS

Please Post label(s) and/or FILL:

PATIENT IDENTIFICATION:

*Name: *Gender: F ☐ M ☐

*D.B.: / / Identification number:

Adress:

E-mail: Telephone:

REFFERING DOCTOR

***Name:** ***ID number:**

***Hospital / Service:** **Telephone:**

Do you authorize the report to sent by e-mail? Yes ☐ No ☐
If yes, please write your **institutional email** address :

***Informed Consent** (to be filled by the referring doctor):

I hereby declare that the patient informed consent for diagnosis was obtained. Yes ☐ No ☐

I hereby declare that the patient informed consent for investigation was obtained. Yes ☐ No ☐

***Mandatory**

***CLINICAL DATA**

Diagnosis: Inicial Diagnosis ☐ Relapse / Progressive Disease ☐

Therapy: Yes ☐ No ☐ Describe:

SPECIMEN DETAILS

Blood – Cllection Date: Collection Time:

FFPE – *Exam n.º: ****Resection / Biopsy Date :**

Surgical resection ☐ Biopsy ☐ Fine Needle Biopsy ☐ *Cell-block* ☐ Other:

Parafinn Block ☐ **Parafinn Sections** ☐ Macrodissection ☐ Yes ☐ No ***% Células Neoplásicas:**

Any other relevant information (main contaminants, blood, necrosis or other):

*** Pathologist:** **ID number:**

***E-mail/Telephone:** **Hospital / Service:**

SNS code in blue

NGS Panels

☐ 34900 Biomarkers Panel for Solid Tumours

Hotspots - 35 genes: *AKT1; ALK; AR; BRAF; CDK4; CTNNB1; DDR2; EGFR; ERBB2 (HER2); ERBB3 (HER3); ERBB4 (HER4); ESR1; FGFR2; FGFR3; GNA11; GNAQ; HRAS; IDH1; IDH2; JAK1; JAK2; JAK3; KIT; KRAS; MAP2K1 (MEK1); MAP2K2 (MEK2); MET; MTOR; NRAS; PDGFRA; PIK3CA; RAF1; RET; ROS1; SMO*
Fusions (23 genes): *ABL1; AKT3; ALK; AXL; BRAF; EGFR; ERBB2 (HER2); ERG; ETV1; ETV4; ETV5; FGFR1; FGFR2; FGFR3; MET; NTRK1; NTRK2; NTRK3; PDGFRA; PPARG; RAF1; RET; ROS1*
CNVs (19 genes): *ALK; AR; BRAF; CCND1; CDK4; CDK6; EGFR; ERBB2 (HER2); FGFR1; FGFR2; FGFR3; FGFR4; KIT; KRAS; MET; MYC; MYCN; PDGFRA; PIK3CA*

☐ 34900 Bladder Panel

Hotspots: *AKT1; ALK; BRAF*; *DDR2*; *EGFR*; *FGFR2*; *FGFR3*; *ERBB2* (*HER2*); *ERBB3* (*HER3*); *ERBB4* (*HER4*); *KRAS*; *MAP2K1*; *MET; NRAS; PIK3CA; RET; ROS1*
Fusions: *ALK*; *FGFR1*; *FGFR2*; *FGFR3*; *MET* (*skipping* exon 14); *NTRK1*; *NTRK2*; *NTRK3; ROS1*; *RET*
CNVs: *EGFR*; *FGFR1; FGFR2; ERBB2* (*HER2*); *KRAS*; *MET*

☐ 34900 BRCA Panel– Pack 1

Genes: *BRCA1* and *BRCA2*
insAlu (blood) + NGS (blood or FFPE) + MLPA (blood) *

☐ 34900 BRCA – Pack 2

Genes: *BRCA1* and *BRCA2*
insAlu (blood) + NGS (blood or FFPE) *

☐ 34900 CCR Panel

Hotspots: *BRAF*; *EGFR; ERBB2* (*HER2*); *ERBB3* (*HER3*); *KRAS; NRAS; PIK3CA*
Fusions: *NTRK1*; *NTRK2*; *NTRK3*
CNVs: *ERBB2* (*HER2*); *MET*

☐ 34900 Breast Panel

Hotspots: *AKT1; ERBB2* (*HER2*); *ESR1; PIK3CA*
Fusions: *FGFR1*; *NTRK1*; *NTRK2*; *NTRK3*
CNVs: *ERBB2* (*HER2*); *FGFR1*; *FGFR2*

☐ 34900 Lung Panel

Hotspots: *AKT1; ALK; BRAF*; *DDR2*; *EGFR*; *FGFR2*; *FGFR3*; *ERBB2* (*HER2*); *ERBB3* (*HER3*); *ERBB4* (*HER4*); *KRAS*; *MAP2K1*; *MET; NRAS; PIK3CA; RET; ROS1*
Fusions: *ALK*; *FGFR1*; *FGFR2*; *FGFR3*; *MET* (*skipping* exon 14); *NTRK1*; *NTRK2*; *NTRK3; ROS1*; *RET*
CNVs: *EGFR*; *FGFR1; FGFR2; ERBB2* (*HER2*); *KRAS*; *MET*

☐ 34900 Thyroid Panel

Hotspots: *BRAF; HRAS; KRAS; NRAS; PIK3CA; RET*
Fusions: *ALK; BRAF; NTRK1; NTRK2; NTRK3; PPARG; RET*

*For the somatic study request we recommend sending both blood and FFPE samplesangue juntamente com o pedido. It includes testing for mutation origin (germline or somatic).

GenoMed, Diagnósticos de Medicina Molecular, SA
Av. Prof. Egas Moniz, Ed. Reynaldo dos Santos, Piso 4, sala 4.19, 1649-028 Lisboa
219 369 920 | laboratorio.genomed@synlab.pt | www.genomed.pt

GENOMED
A MEMBER OF SYNLAB

Tests by Cancer Type

Colorectal Cancer

☐ 34900 ***KRAS***, with ***NRAS*** and ***BRAF*** (V600) reflex testing
☐ 34650 **MSI** - Microsatellite instability (1)
☐ 34900 ***MLH1*** promoter hypermethylation

Endometrial Cancer

☐ 34900 ***POLE*** (exons 9, 11, 13, 14)
☐ 34650 **MSI** - Microsatellite instability (1)
☐ 34900 ***MLH1*** promoter hypermethylation
☐ 34900 ***TP53***

Melanoma

☐ 34900 **Panel: *BRAF*** (V600); ***KIT*** (exon 11); ***NRAS*** (codons 12, 13, 61)

GIST

☐ 34900 **Panel: *KIT*** (exons 9, 11, 13, 14, 17); ***PDGFRA*** (exons 12, 14, 18)

Brain Cancer

☐ 36314 ***BRAF*** (V600)
☐ 34900 ***H3F3A*** (K27M and G34R/V)
☐ 34900 ***HIST1H3B*** (K27M)
☐ 34900 ***IDH1*** (exon 4)
☐ 34900 ***IDH2*** (exon 4)
☐ 34900 ***TERT*** promoter mutations (C228T and C250T)
☐ 36312 ***MGMT*** Promotor methylation
☐ 2x31710 **1p36 e 19q13 -** co-deletion (FISH)
☐ 31710 ***RELA*** (11q13) - rearrangement (FISH)
☐ 31710 ***EGFR*** (7p12) - amplification (FISH)
☐ 31710 ***PTEN*** (10q23.31) - deletion (FISH)
☐ 31710 ***BRAF*** (7q34) - rearrangement (***BRAF::KIAA1549*** and variants) (FISH)
☐ 31710 ***CDKN2A*** (9p21) - deletion (FISH)

Individual Tests

Molecular Genetics

☐ 36314 ***BRAF*** (V600)
☐ 34900 ***H3F3A*** (K27M and G34R/V)
☐ 34900 ***HIST1H3B*** (K27M)
☐ 34900 ***IDH1*** (exon 4)
☐ 34900 ***IDH2*** (exon 4)
☐ 5x34847 ***KIT*** (exons 9, 11, 13, 14, 17)
☐ 34650 **MSI** - Microsatellite instability (1)
☐ 34900 ***MLH1*** promoter hypermethylation
☐ 36312 ***MGMT*** Promotor methylation
☐ 34900 ***NRAS*** (codons 12, 13, 61)
☐ 34900 ***PDGFRA*** (exons 12, 14, 18)
☐ 34900 ***POLE*** (exons 9, 11, 13, 14)
☐ 34900 ***TERT*** promoter mutations (C228T and C250T)
☐ 34900 ***TP53***

Molecular Cytogenetics (FISH)

☐ 2x 31710 **1p36 e 19q13 -** co-deletion
☐ 31710 ***ALK*** (2p23) - rearrangement
☐ 31710 ***BRAF*** (7q34) - rearrangement (***BRAF::KIAA1549*** and variants)
☐ 31710 ***CDKN2A*** (9p21) - deletion
☐ 31710 ***EGFR*** (7p12) - amplification
☐ 31710 ***ERBB2*** (***HER2***) - amplification
☐ 2x31710 ***FGFR1*** (8p12) and ***FGFR2*** (10q26) - amplification
☐ 31710 ***PTEN*** (10q23.31) - deletion
☐ 31710 ***RELA*** (11q13) - rearrangement
☐ 31710 ***ROS1*** (6q22) - rearrangement

☐ 34900 **Others:**_____
_____

Reffering doctor signature: Date: / /

Specimen and shipment information:

- **Sample Rejection Conditions**: Decalcified specimens. Specimens without tumorous tissue.
- We ask a pathology report where possible, for correctly interpret test results.
- When sending sections macrodissection is recommended if tumour cell percentage is lower than 20-30%.
- To perform a correct CNV analysis, the percentage of neoplastic cells in the sample should be higher than a 50%.

Sample type		Volume / Concentration / FFPE conditions		Stability and transport conditions
Peripheral blood in EDTA tube		3 to 6 mL		Up to 48h / Room temperature Up to 72h / Refrigerated
DNA		>5µg with concentration >20ng/µL		Up to 48h / Room temperature > 48h / Refrigerated
FFPE	**NGS**	Parafinn block+ 1 H&E slide with tumour tissue defined (1)	6 sections of 20 µm	Room temperature
	Other Molecular tests		10 sections of 10 µm (1)	
	FISH		3 sections of 50 µm	

(1) – For Microsatellite Instability Testing send Tumor AND Normal epithelial tissue

Informed Consent (mandatory - to be filled by the patient)

I hereby declare that I have read the Privacy Policy of GenoMed® - Diagnósticos de Medicina Molecular, S.A., available at https://genomed.pt/politica-de-privacidade-e-de-cookies/ and I give my consent to the processing of the personal data.

☐ Agree ☐ Not agree

Hereby I _____ [name], _____/_____/_____ [date of birth], give my consent that my / my child´s biological sample will be examined for genetic changes (mutations) in the specified gene(s), related to the diseases / clinical features described above. Herewith I declare that I have been informed about the chances and limitations of the requested testing procedure. I was informed in detail about the consequences resulting from the test results. I agree that the sample may be stored in order to allow repetition of the tests or further related tests in the future. All data about me / my child are subject to medical confidentiality. They can be disclosed to family members or their physicians only with my permission, but not to third parties. I am entitled to revoke this consent at any time.

☐ Agree ☐ Not agree

I agree that my / my child´s tests results and/or clinical data may be used in scientific publications in anonymized form in case of approval of the Ethics Committee .

☐ Agree ☐ Not agree

(According to the Direction of General Health updated standard 015/2013)

Patient's Signature: Date: / /